Sign in or create an account to add this stock to your watchlist.
About ProQR Therapeutics (NASDAQ:PRQR)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company has a research collaboration agreement with Galapagos N.V. to discover Axiomer Editing Oligonucleotides against fibrosis targets. ProQR Therapeutics N.V. has a partnership agreement with Foundation Fighting Blindness to develop QR-421a for usher syndrome 2A caused by an exon 13 mutation of the causative USH2A gene. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000
Debt
Debt-to-Equity Ratio0.19
Current Ratio5.64
Quick Ratio5.64
Price-To-Earnings
Trailing P/E Ratio-2.68
Forward P/E Ratio-3.37
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.39 per share
Price / Book3.71
Profitability
EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-128.44%
Return on Assets-93.68%
Miscellaneous
Employees133
Outstanding Shares31,860,000
ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions
What is ProQR Therapeutics' stock symbol?
ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics' earnings last quarter?
ProQR Therapeutics (NASDAQ:PRQR) released its earnings results on Wednesday, May, 16th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.06. View ProQR Therapeutics' Earnings History.
When is ProQR Therapeutics' next earnings date?
What price target have analysts set for PRQR?
4 brokers have issued 12-month target prices for ProQR Therapeutics' stock. Their forecasts range from $4.50 to $40.00. On average, they expect ProQR Therapeutics' stock price to reach $19.1250 in the next year. View Analyst Ratings for ProQR Therapeutics.
Who are some of ProQR Therapeutics' key competitors?
Some companies that are related to ProQR Therapeutics include Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Aclaris Therapeutics (ACRS), BeyondSpring (BYSI), Lannett (LCI), Geron (GERN), Prothena (PRTA), Akebia Therapeutics (AKBA), ChemoCentryx (CCXI), AC Immune (ACIU), CannTrust (CNTTF), StemlineTherapeutics (STML) and Clementia Pharmaceuticals (CMTA).
Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the folowing people:
- Mr. Daniel A. de Boer, Chief Exec. Officer and Member of Management Board (Age 35)
- Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Corp. Sec. & Member-Management Board (Age 54)
- Ms. Smital Shah, Chief Financial Officer (Age 42)
- Mr. Joost Clement, Director of HR
- Mr. Bart Klein, Sr. VP of Intellectual Property
Has ProQR Therapeutics been receiving favorable news coverage?
News articles about PRQR stock have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProQR Therapeutics earned a news impact score of 0.15 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are ProQR Therapeutics' major shareholders?
ProQR Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (2.07%), Sabby Management LLC (0.54%), Opus Point Partners Management LLC (0.48%) and JPMorgan Chase & Co. (0.10%). View Institutional Ownership Trends for ProQR Therapeutics.
Which major investors are selling ProQR Therapeutics stock?
Which major investors are buying ProQR Therapeutics stock?
How do I buy shares of ProQR Therapeutics?
Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics' stock price today?
One share of PRQR stock can currently be purchased for approximately $5.15.
How big of a company is ProQR Therapeutics?
ProQR Therapeutics has a market capitalization of $160.90 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 133 workers across the globe.
How can I contact ProQR Therapeutics?
ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]
MarketBeat Community Rating for ProQR Therapeutics (PRQR)
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
ProQR Therapeutics (NASDAQ:PRQR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for ProQR Therapeutics in the last 12 months. Their average twelve-month price target is $19.1250, suggesting that the stock has a possible upside of 271.36%. The high price target for PRQR is $40.00 and the low price target for PRQR is $4.50. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.1250 | $19.1250 | $24.00 | $24.00 |
| Price Target Upside: | 271.36% upside | 548.31% upside | 700.00% upside | 272.09% upside |
ProQR Therapeutics (NASDAQ:PRQR) Consensus Price Target History
ProQR Therapeutics (NASDAQ:PRQR) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
ProQR Therapeutics (NASDAQ:PRQR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ProQR Therapeutics (NASDAQ PRQR) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 31.98%
ProQR Therapeutics (NASDAQ PRQR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
ProQR Therapeutics (NASDAQ PRQR) News Headlines
| Source: |
|
ProQR Therapeutics (NASDAQ:PRQR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ProQR Therapeutics (NASDAQ:PRQR) Income Statement, Balance Sheet and Cash Flow Statement
ProQR Therapeutics (NASDAQ PRQR) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
